TC Avastin. ICORG 08-10, V6

OBJECTIVES: Primary * Assess the feasibility of the combination of adjuvant bevacizumab, docetaxel, and cyclophosphamide in patients with early-stage HER2-negative high-risk breast cancer. * Determine the safety of this regimen with regards to cardiac toxicity, hypertension, and bleeding complications in these patients. Secondary * Evaluate the efficacy of this regimen by measuring Topo II overexpression in these patients. OUTLINE: This is a multicenter study. Patients will receive 4 cycles of Docetaxel 75mg/m2 + 4 cycles of Cyclophosphamide 600mg/m2 (each cycle lasts 21 days) (+/- 3 days if a due date could not be met because of public holidays, etc) and concomitant Avastin (Bevacizumab) 15mg/kg q 3weeks for treatment duration of one year. Bevacizumab at a dose of 15mg/kg will be administered as an intravenous infusion every 3 weeks for a treatment period of one year, regardless of missed doses. Patients will be followed up through 5 years (i.e. from the time of registration through to end of Year 5/ 1 year treatment and 4 years follow up).